Monkeypox Is A Different Drug Development Ballgame From COVID-19

Company Shifts Focus To Randomized Trials For EUA

SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.

SIGA's smallpox drug, Tpoxx, is moving through multiple clinical trials for monkeypox worldwide • Source: Shutterstock

Despite early fears of a large-scale epidemic, the monkeypox outbreak in the US has already begun to plateau. But despite the public health emergency that the Department of Health and Human Services declared on 4 August, the development of drugs and vaccines to address monkeypox differs markedly from development of countermeasures for the COVID-19 pandemic.

It is into this complex environment that SIGA Technologies, Inc has stepped, as the maker of the antiviral drug Tpoxx (tecovirimant), which has US Food and Drug Administration approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.